Kyverna Therapeutics

Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for people with autoimmune diseases. Its mission is to pursue the curative potential of cell therapy and create life-changing medicines, with an emphasis on neurologic autoimmune conditions. The company adapts CAR T-cell therapy, established in B-cell-driven blood cancers, for autoimmune disease. Its approach aims to deplete disease-associated B cells, reset the immune system, and support long-term, treatment-free remission.

Kyverna’s lead autologous, CD19-targeting CAR T-cell candidate is mivocabtagene autoleucel (miv-cel, KYV-101), which it is evaluating across multiple B-cell-driven autoimmune diseases. Its pipeline includes a completed registrational trial in stiff person syndrome and an ongoing registrational trial for generalized myasthenia gravis, alongside other company-sponsored and investigator-initiated studies. Kyverna also pursues next-generation cell therapy innovations and additional indications. The company provides information about clinical trial participation and expanded access, which may be considered when alternative treatment options have been exhausted.